Adi Geffen
ceo Eleven Therapeutics
Adi Gilboa-Geffen is a seasoned technology executive currently serving as the Chief Technology Officer at Eleven Therapeutics. With a strong foundation in research and development, Adi’s expertise spans across product innovation, scientific research, and leadership, primarily focusing on the biotechnology and life sciences industries. Adi’s career trajectory is marked by significant leadership roles and contributions to the biotech industry, including roles as Senior VP of Product R&D at Eleven Therapeutics and Advisor at DOTS Technology Corp. Adi’s professional overview includes a unique blend of scientific expertise, product development acumen, and leadership capability, positioning for continued impact and growth in the biotech field.
Seminars
- Leveraging the xRNA™ to overcome the stability limitations of conventional mRNA, achieving an ~100-fold improvement in Area Under the Curve (AUC) through highthroughput combinatorial screening
- Demonstrating robust pharmacokinetic durability with NHP half-life Weekly xRNAencoded GLP-1 agonist (xGLP1) administration outperformed gold standard protocols of daily-dosed FDA-approved therapeutics in diet-induced obesity mice, producing substantial weight loss and improved fasting glucose
- Moreover, single-dose administration of xGLP-1 maintained significant HbA1c reduction and functional peptide levels for three weeks in genetic diabetes (db/ db mice) xRNA thus potentially, enables transformation from transient peptide administration to monthly or quarterly therapeutic regimens, utilizing a safe, titratable modality compatible with at-home patient-self-administration of intramuscular delivery
